HomeCompareCAH vs ECL

CAH vs ECL: Dividend Comparison 2026

CAH yields 0.99% · ECL yields 1.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ECL wins by $10.2K in total portfolio value
10 years
CAH
CAH
● Live price
0.99%
Share price
$206.31
Annual div
$2.04
5Y div CAGR
5.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$185.04
Full CAH calculator →
ECL
ECL
● Live price
1.05%
Share price
$262.49
Annual div
$2.76
5Y div CAGR
36.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.8K
Annual income
$3,316.22
Full ECL calculator →

Portfolio growth — CAH vs ECL

📍 ECL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAHECL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAH + ECL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAH pays
ECL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAH
Annual income on $10K today (after 15% tax)
$83.95/yr
After 10yr DRIP, annual income (after tax)
$157.28/yr
ECL
Annual income on $10K today (after 15% tax)
$89.37/yr
After 10yr DRIP, annual income (after tax)
$2,818.79/yr
At 15% tax rate, ECL beats the other by $2,661.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAH + ECL for your $10,000?

CAH: 50%ECL: 50%
100% ECL50/50100% CAH
Portfolio after 10yr
$26.7K
Annual income
$1,750.63/yr
Blended yield
6.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ECL right now

CAH
Analyst Ratings
18
Buy
15
Hold
Consensus: Buy
Price Target
$252.33
+22.3% upside vs current
Range: $220.00 — $275.00
Altman Z
4.8
Piotroski
5/9
ECL
Analyst Ratings
26
Buy
10
Hold
1
Sell
Consensus: Buy
Price Target
$326.30
+24.3% upside vs current
Range: $300.00 — $345.00
Altman Z
4.8
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAH buys
0
ECL buys
0
No recent congressional trades found for CAH or ECL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAHECL
Forward yield0.99%1.05%
Annual dividend / share$2.04$2.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.6%36.1%
Portfolio after 10y$21.6K$31.8K
Annual income after 10y$185.04$3,316.22
Total dividends collected$1.4K$10.4K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusBuyBuy
Analyst price target$252.33$326.30

Year-by-year: CAH vs ECL ($10,000, DRIP)

YearCAH PortfolioCAH Income/yrECL PortfolioECL Income/yrGap
1← crossover$10,804$104.30$10,843$143.10$39.00ECL
2$11,672$111.21$11,799$197.37$127.00ECL
3$12,607$118.57$12,899$273.19$292.00ECL
4$13,616$126.40$14,181$379.86$565.00ECL
5$14,704$134.73$15,705$531.22$1.0KECL
6$15,877$143.59$17,553$748.30$1.7KECL
7$17,142$153.02$19,845$1,063.78$2.7KECL
8$18,504$163.04$22,764$1,529.81$4.3KECL
9$19,973$173.70$26,590$2,232.07$6.6KECL
10$21,557$185.04$31,768$3,316.22$10.2KECL

CAH vs ECL: Complete Analysis 2026

CAHHealthcare

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Full CAH Calculator →

ECLMaterials

Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through Global Industrial, Global Institutional & Specialty, and Global Healthcare & Life Sciences segments. The Global Industrial segment offers water treatment and process applications, and cleaning and sanitizing solutions to manufacturing, food and beverage processing, transportation, chemical, metals and mining, power generation, pulp and paper, commercial laundry, petroleum, refining, and petrochemical industries. The Global Institutional & Specialty segment provides specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government and education, and retail industries. Its Global Healthcare & Life Sciences segment offers specialized cleaning and sanitizing products to the healthcare, personal care, and pharmaceutical industries, such as infection prevention and surgical solutions, and end-to-end cleaning and contamination control solutions under the Ecolab, Microtek, and Anios brand names. The company's Other segment offers pest elimination services to detect, eliminate, and prevent pests, such as rodents and insects in restaurants, food and beverage processors, educational and healthcare facilities, hotels, quick service restaurant and grocery operations, and other institutional and commercial customers. This segment also provides colloidal silica for binding and polishing applications in semiconductor, catalyst, and aerospace component manufacturing, as well as chemical industries; and products and services that manage wash process through custom designed programs, premium products, dispensing equipment, water and energy management, and reduction, as well as real time data management. It sells its products through field sales and corporate account personnel, distributors, and dealers. The company was founded in 1923 and is headquartered in Saint Paul, Minnesota.

Full ECL Calculator →
📬

Get this CAH vs ECL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAH vs SCHDCAH vs JEPICAH vs OCAH vs KOCAH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.